SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK821.62m
- SEK756.91m
Brief: Synact To Report About Phase IIA Of AP1189 In Q2 2020, Not Q1
Brief: SynAct Says Approval From Swedish Medical Product Agency, Swedish Ethical Review Authority On Phase IIa Study With AP1189
Brief: Synact Pharma Carries Out Directed Issue And Fully-Guaranteed Rights Issue
Brief: Synact Pharma Q2 Pre-Tax Loss Narrows To SEK 7.3 Million
Brief: Synact Pharma Secures Bridge Loan Financing Of Around SEK 10 Mln
Brief: SynAct Pharma Q1 Pretax Loss Widens To SEK 4.7 Mln
Brief: Synact Pharma Reports Positive Phase 1 Results For Drug Candidate AP1189
Brief: Synact Pharma Q2 Pre-Tax Loss Widens To SEK 9.9 Million
Brief: Synact Pharma AB Rights Issue Oversubscribed
Brief: SynAct Pharma Q1 Pre-Tax Loss Slightly Widens To SEK 3.5 Million
Brief: Synact Pharma Proposes Rights Issue Of SEK 22.4 Million
Brief: SynAct Pharma Q4 Pre-Tax Loss Narrows To SEK 7.3 Million
Brief: Synact Pharma Q2 pre-tax loss at SEK 5.2 million
Brief: SynAct Pharma raises proceeds of SEK 1 mln through exercise of warrants of series TO